UK markets closed

Sandoz Group AG (SDZ.SW)

Swiss - Swiss Delayed price. Currency in CHF
Add to watchlist
31.89-0.29 (-0.90%)
At close: 05:30PM CEST
Full screen
Previous close32.18
Open32.24
Bid0.00 x N/A
Ask0.00 x N/A
Day's range31.80 - 32.24
52-week range22.70 - 32.80
Volume824,905
Avg. volume1,381,239
Market cap13.71B
Beta (5Y monthly)N/A
PE ratio (TTM)199.31
EPS (TTM)0.16
Earnings dateN/A
Forward dividend & yield0.45 (1.41%)
Ex-dividend date03 May 2024
1y target est36.74
  • GlobeNewswire

    Improving access for patients: launch of Lisdexamfetamine further broadens Sandoz Canada portfolio

    Michel Robidoux Michel Robidoux PrSandoz® Lisdexamfetamine, one of first generic equivalents of Vyvanse*, available on Canadian marketApproved for all indications of reference medicine: Attention Deficit Hyperactivity Disorder and Binge Eating Disorder in adultsPrSandoz® Amoxicillin, PrSandoz® Desvenlafaxine and PrSandoz® Riociguat also joined Sandoz Canada’s generics portfolio this spring BOUCHERVILLE, Quebec, June 05, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada announced today the launch of PrSando

  • Globe Newswire

    Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

    Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia®EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and qualityApproved for treatment of cancer-related bone disease and osteoporosis respectively Basel, May 22, 2024 – Sandoz, the global leader in gener

  • Globe Newswire

    Sandoz reports first quarter 2024 sales

    Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD)Biosimilar business growing 21% in constant currencies All regions contributing to growthAcquisition of CIMERLI® (ranibizumab-eqrn) completed in March 2024 Basel, May 7, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the f